Identification of a major epitope by anti-interferon-γ autoantibodies in patients with mycobacterial disease

Nature Medicine

Volumn 22, Issue 9, 2016, Pages 994-1001

  Lin, Chia Hao ^a   Chi, Chih Yu ^a,b,c   Shih, Han Po ^a   Ding, Jing Ya ^a   Lo, Chia Chi ^a   Wang, Shang Yu ^a,d   Kuo, Chen Yen ^a,d   Yeh, Chun Fu ^a,d,e   Tu, Kun Hua ^a,d,e   Liu, Shou Hsuan ^a,d,e   Chen, Hung Kai ^f   Ho, Chen Hsuan ^f   Ho, Mao Wang ^b   Lee, Chen Hsiang ^e   Lai, Hsin Chin ^a   Ku, Cheng Lung ^a,d,g  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^f DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIMYCOBACTERIAL AGENT; AUTOANTIBODY; EPITOPE ERASED VARIANT OF INTERFERON GAMMA; FUNGAL PROTEIN; GAMMA INTERFERON 1 131; GAMMA INTERFERON ANTIBODY; GAMMA INTERFERON DERIVATIVE; GAMMA INTERFERON RECEPTOR; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 12P40; NEUTRALIZING ANTIBODY; NOC2 PROTEIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT PROTEIN; STAT1 PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; AUTOANTIGEN; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; INTERFERON RECEPTOR;

ADULT; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN STRUCTURE; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; DRUG EFFICACY; EPITOPE MAPPING; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MOLECULAR MIMICRY; MYCOBACTERIOSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; ANIMAL; ASPERGILLUS; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HAPLOTYPE; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ASPERGILLUS; AUTOANTIBODIES; AUTOANTIGENS; CASE-CONTROL STUDIES; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; EPITOPES, B-LYMPHOCYTE; FUNGAL PROTEINS; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOBLOTTING; INTERFERON-GAMMA; INTERLEUKIN-12 SUBUNIT P40; MYCOBACTERIUM INFECTIONS; RATS; RECEPTORS, INTERFERON;

EID: 84982102692     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4158     Document Type: Article

References (46)

1. Döffinger, R. et al. Autoantibodies to interferon-γ in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin. Infect. Dis. 38, e10-e14 (2004).
2. Höflich, C. et al. Naturally occurring anti-IFN-γ autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 103, 673-675 (2004).
3. Kampmann, B. et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-γ. J. Clin. Invest. 115, 2480-2488 (2005).
4. Patel, S.Y. et al. Anti-IFN-γ autoantibodies in disseminated nontuberculous mycobacterial infections. J. Immunol. 175, 4769-4776 (2005).
5. Puel, A. et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J. Immunol. 180, 647-654 (2008).
6. Puel, A. et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207, 291-297 (2010).
7. Browne, S.K. et al. Adult-onset immunodeficiency in Thailand and Taiwan. N. Engl. J. Med. 367, 725-734 (2012).
8. Chi, C.Y. et al. Anti-IFN-γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1∗16:02 and HLA-DQB1∗05:02 and the reactivation of latent varicella-zoster virus infection. Blood 121, 1357-1366 (2013).
9. Rosen, L.B. et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J. Immunol. 190, 3959-3966 (2013).
10. Lee, W.I. et al. Patients with inhibitory and neutralizing auto-antibodies to interferon-γ resemble the sporadic adult-onset phenotype of mendelian susceptibility to mycobacterial disease (MSMD) lacking bacille Calmette-Guerin (BCG)-induced diseases. Immunobiology 218, 762-771 (2013).
11. Browne, S.K. Anticytokine autoantibody-associated immunodeficiency. Annu. Rev. Immunol. 32, 635-657 (2014).
12. Rosen, L.B. et al. Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated/extrapulmonary nocardiosis. Clin. Infect. Dis. 60, 1017-1025 (2015).
13. Chi, C.Y. et al. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine (Baltimore) 95, e3927 (2016).
14. Levin, M. et al. Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene? Lancet 345, 79-83 (1995).
15. Casanova, J.L. et al. Idiopathic disseminated bacillus Calmette-Guérin infection: a French national retrospective study. Pediatrics 98, 774-778 (1996).
16. Bustamante, J., Boisson-Dupuis, S., Abel, L. & Casanova, J.L. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin. Immunol. 26, 454-470 (2014).
17. Puel, A. & Casanova, J.L. Autoantibodies against cytokines: back to human genetics. Blood 121, 1246-1247 (2013).
18. Sfriso, P. et al. Infections and autoimmunity: the multifaceted relationship. J. Leukoc. Biol. 87, 385-395 (2010).
19. Rowley, D. & Jenkin, C.R. Antigenic cross-reaction between host and parasite as a possible cause of pathogenicity. Nature 193, 151-154 (1962).
20. Cusick, M.F., Libbey, J.E. & Fujinami, R.S. Molecular mimicry as a mechanism of autoimmune disease. Clin. Rev. Allergy Immunol. 42, 102-111 (2012).
21. van den Berg, B. et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat. Rev. Neurol. 10, 469-482 (2014).
22. Kain, R. et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat. Med. 14, 1088-1096 (2008).
23. Ku, C.L. et al. Anti-IFN-γ autoantibodies are strongly associated with HLA-DR∗15:02/16:02 and HLA-DQ∗05:01/05:02 across Southeast Asia. J. Allergy Clin. Immunol. 137, 945-948.e8 (2016).
24. Emini, E.A., Hughes, J.V., Perlow, D.S. & Boger, J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J. Virol. 55, 836-839 (1985).
25. Larsen, J.E., Lund, O. & Nielsen, M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2, 2 (2006).
26. Bordoli, L. et al. Protein structure homology modeling using SWISS-MODEL workspace. Nat. Protoc. 4, 1-13 (2009).
27. Ealick, S.E. et al. Three-dimensional structure of recombinant human interferon-γ. Science 252, 698-702 (1991).
28. Walter, M.R. et al. Crystal structure of a complex between interferon-γ and its soluble high-affinity receptor. Nature 376, 230-235 (1995).
29. Thiel, D.J. et al. Observation of an unexpected third receptor molecule in the crystal structure of human interferon-γ receptor complex. Structure 8, 927-936 (2000).
30. Lundell, D. et al. The carboxyl-terminal region of human interferon gamma is important for biological activity: mutagenic and NMR analysis. Protein Eng. 4, 335-341 (1991).
31. Savan, R., Ravichandran, S., Collins, J.R., Sakai, M. & Young, H.A. Structural conservation of interferon γ among vertebrates. Cytokine Growth Factor Rev. 20, 115-124 (2009).
32. Basham, T.Y. & Merigan, T.C. Recombinant interferon-γ increases HLA-DR synthesis and expression. J. Immunol. 130, 1492-1494 (1983).
33. Seelig, G.F., Wijdenes, J., Nagabhushan, T.L. & Trotta, P.P. Evidence for a polypeptide segment at the carboxyl terminus of recombinant human gamma interferon involved in expression of biological activity. Biochemistry 27, 1981-1987 (1988).
34. Wang, Y. et al. Characterization of pathogenic human monoclonal autoantibodies against GM-CSF. Proc. Natl. Acad. Sci. USA 110, 7832-7837 (2013).
35. Piccoli, L. et al. Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat. Commun. 6, 7375 (2015).
36. Baxter, C.G. et al. Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. Clin. Microbiol. Infect. 19, E197-E204 (2013).
37. Barnes, P.D. & Marr, K.A. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect. Dis. Clin. North Am. 20, 545-561 (2006).
38. Nguyen, L.D., Viscogliosi, E. & Delhaes, L. The lung mycobiome: an emerging field of the human respiratory microbiome. Front. Microbiol. 6, 89 (2015).
39. Chaudhary, N., Staab, J.F. & Marr, K.A. Healthy human T-Cell Responses to Aspergillus fumigatus antigens. PLoS One 5, e9036 (2010).
40. Oldstone, M.B. Molecular mimicry and immune-mediated diseases. FASEB J. 12, 1255-1265 (1998).
41. Neal, C.O. et al. Global population structure of Aspergillus terreus inferred by ISSR typing reveals geographical subclustering. BMC Microbiol. 11, 203 (2011).
42. Browne, S.K. et al. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood 119, 3933-3939 (2012).
43. Rao, V.K. et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr. Blood Cancer 52, 847-852 (2009).
44. Keating, G.M. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70, 1445-1476 (2010).
45. Sologuren, I. et al. Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum. Mol. Genet. 20, 1509-1523 (2011).
46. Smith, K. et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 4, 372-384 (2009).